Apollo Therapeutics Raises $260 Million in Series C to Advance Drug Development

Apollo Therapeutics, a UK-based biopharmaceutical startup, has closed the second tranche of its Series C funding round, raising an additional $33.5 million

The company has now raised a total of $260 million

The round was led by Patient Square Capital with participation from new investors including M&G plc and two of the largest US public pension plans, as well as existing investors, including Rock Springs Capital

Apollo Therapeutics plans to use the fresh funds to advance its pipeline programs through clinical development and to invest in its drug discovery and development activities

The company focuses on translating fundamental medical research into medicines, employing a ‘hub-and-spoke’ approach to manage its portfolio.